Effects of Oral Magnesium Supplementation on Patients With Type 2 Diabetes

Evaluation of the Effects of Oral Magnesium Supplementation on Glycemic Control and Inflammation Among Patients With Type 2 Diabetes

A total of 74 Adult Patients with type 2 diabetes mellitus (T2D) will be enrolled and randomized into 2 groups. The intervention group will receive oral magnesium (Mg) supplementation. The study objectives are:

1. To estimate level of Mg (total and ionized) in patient with type 2 DM.
2. To determine the effect of Mg supplementation for diabetic patient on serum Mg level, glycemic control and level of inflammation.
3. To assess the correlation between serum Mg level and glycemic control and level of inflammatory mediators (CRP)

A total of 74 Adult Patients of both genders who had been diagnosed with T2D and are on oral anti-hyperglycemic drug and their HbA1C between 7and 8 %, will be enrolled in the study. Initially the study protocol will be explained & informed written consent will be obtained from all participants. All subjects will be evaluated to ensure that they meet the eligibility criteria through: Full history taking, complete physical examination and investigations. the intervention group will receive oral magnesium (Mg) supplementation for 3 months (250 mg of elemental magnesium daily). The primary outcome is to determine the effect of Mg supplementation for diabetic patient on serum Mg level, glycemic control and level of inflammation.

Inclusion Criteria:

• Patients with type 2 diabetes with HbA1C between 7 and 8%.
• Both genders will be included in this study.

Exclusion Criteria:

• Patients on insulin.

  • Patients on diuretics or angiotensin-converting enzyme inhibitors in the last 2 weeks.
  • Patients taking Mg containing supplements within 3 months.
  • Patients with significant gastrointestinal disorders (eg, chronic diarrhea).
  • Patients with impaired renal functions (eGFR< 60 mL/min).
  • Heart block or heart failure
  • Patients treated with aldosterone antagonists.
  • Pregnant patients
  • Patients with evidence of infection.
  • Patients with chronic inflammatory conditions eg, SLE